Artal Group »

Remitly Global shares owned by Artal Group

Quarter-by-quarter ownership of Remitly Global (RELY) shares owned by Artal Group from 13F filings

Historical chart of Artal Group investment in Remitly Global

Tip: Access up to 7 years of quarterly data

All positions including Remitly Global held by Artal Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Remitly Global by Artal Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $486k 25k 19.44

More positions owned by Artal Group

Cava Group Ord (CAVA)
Scholar Rock Hldg Corp (SRRK)
Lexicon Pharmaceuticals Com New (LXRX)
Cytokinetics Com New (CYTK)
Apellis Pharmaceuticals (APLS)
Beigene Sponsored Adr (BGNE)
Kymera Therapeutics (KYMR)
Amicus Therapeutics (FOLD)
Morphic Hldg (MORF)
Springworks Therapeutics (SWTX)
Silence Therapeutics Ads (SLN)
Revolution Medicines (RVMD)
Argenx Se Sponsored Adr (ARGX)
Neumora Therapeutics (NMRA)
Arrowhead Pharmaceuticals (ARWR)

View all positions for Artal Group

Top funds holding Remitly Global

Naspers
Vanguard Group
Baillie Gifford & Co
Jpmorgan Chase & Co
Wellington Management Company
Citadel Advisors
Millennium Management
Massachusetts Financial Services
Lord, Abbett & Co
Dimensional Fund Advisors
Norges Bank Investment Management
Alliancebernstein
Charles Schwab Investment Management
Alyeska Investment Group
Cercano Management

View all funds holding Remitly Global